MX2011008176A - Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. - Google Patents

Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.

Info

Publication number
MX2011008176A
MX2011008176A MX2011008176A MX2011008176A MX2011008176A MX 2011008176 A MX2011008176 A MX 2011008176A MX 2011008176 A MX2011008176 A MX 2011008176A MX 2011008176 A MX2011008176 A MX 2011008176A MX 2011008176 A MX2011008176 A MX 2011008176A
Authority
MX
Mexico
Prior art keywords
anticancer agents
spiroindolinone derivatives
spiroindolinone
derivatives
agents
Prior art date
Application number
MX2011008176A
Other languages
English (en)
Inventor
Zhuming Zhang
Jing Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011008176A publication Critical patent/MX2011008176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se relaciona con los compuestos de la fórmula (I), o una sal o un éster farmacéuticamente aceptable del mismo en donde X, Y, R1, R2 son de acuerdo a como aquí se ha descrito. Los compuestos tienen utilidad como agentes antiproliferativos, especialmente, como agentes anticancerígenos.
MX2011008176A 2009-02-17 2010-02-12 Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. MX2011008176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15308909P 2009-02-17 2009-02-17
PCT/EP2010/051757 WO2010094622A1 (en) 2009-02-17 2010-02-12 3, 3' -spiroindolinone derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
MX2011008176A true MX2011008176A (es) 2011-08-17

Family

ID=42062321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008176A MX2011008176A (es) 2009-02-17 2010-02-12 Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.

Country Status (12)

Country Link
US (1) US8217051B2 (es)
EP (1) EP2398801A1 (es)
JP (1) JP2012517976A (es)
KR (1) KR20110104568A (es)
CN (1) CN102356082A (es)
AU (1) AU2010215554A1 (es)
BR (1) BRPI1008899A2 (es)
CA (1) CA2751767A1 (es)
IL (1) IL213920A0 (es)
MX (1) MX2011008176A (es)
SG (1) SG173629A1 (es)
WO (1) WO2010094622A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939778C (en) * 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2142562B1 (en) 2007-03-28 2013-07-03 President and Fellows of Harvard College Stitched polypeptides
EP2603600B1 (en) 2010-08-13 2018-11-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CA3040840A1 (en) 2016-10-17 2018-04-26 Daiichi Sankyo Company, Limited Combined use of mdm2 inhibitor and dna methyltransferase inhibitor for cancer treatment
CN115772171A (zh) * 2021-09-09 2023-03-10 沈阳药科大学 一价金催化的螺[吲哚啉-3,3’-哌啶]骨架的合成方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE63543T1 (de) 1984-02-07 1991-06-15 Pfizer 2-oxindolzwischenprodukte.
DE3714473A1 (de) 1987-04-30 1988-11-10 Basf Ag Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CZ2002203A3 (cs) 1999-07-21 2002-08-14 Astrazeneca Ab Spirooxindolové deriváty
CA2752738C (en) 2005-02-22 2014-05-27 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
AU2007224452A1 (en) * 2006-03-13 2007-09-20 F. Hoffmann-La Roche Ag Spiroindolinone derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
BRPI0719210A2 (pt) * 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008080822A1 (en) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Epimerization methodologies for recovering stereo isomers in high yield and purity
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives

Also Published As

Publication number Publication date
AU2010215554A1 (en) 2011-07-28
JP2012517976A (ja) 2012-08-09
IL213920A0 (en) 2011-07-31
WO2010094622A1 (en) 2010-08-26
US8217051B2 (en) 2012-07-10
US20100210674A1 (en) 2010-08-19
CN102356082A (zh) 2012-02-15
CA2751767A1 (en) 2010-08-26
BRPI1008899A2 (pt) 2018-03-13
SG173629A1 (en) 2011-09-29
EP2398801A1 (en) 2011-12-28
KR20110104568A (ko) 2011-09-22

Similar Documents

Publication Publication Date Title
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
TW200801000A (en) Spiroindolinone derivatives
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
IL205506A0 (en) Spiroindolinone derivatives as anticancer agents
IL193620A0 (en) Spiroindolinone derivatives
IL205354A0 (en) Spiroindolinone derivatives
TW200612958A (en) Substituted imidazole derivatives
MY160596A (en) Spiroindolinone pyrrolidines
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
IN2012DN02487A (es)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
ZA201002987B (en) Tropane compounds
WO2009057079A3 (en) Novel pyrimidine derivatives
MX2011007886A (es) Derivado de espiroindolinona piridina.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
IL208025A0 (en) Spiroindolinone derivatives
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
GB201020397D0 (en) Compounds
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.
NZ599916A (en) 5-amino-4-hydroxypentoyl amides
UA103497C2 (en) Substituted pyrrolidine-2-carboxamides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal